Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Short term Debt (2018 - 2026)

Profound Medical has reported Short term Debt over the past 7 years, most recently at $4.5 million for Q3 2025.

  • For Q3 2025, Short term Debt changed N/A year-over-year to $4.5 million; the TTM value through Sep 2025 reached $4.5 million, changed N/A, while the annual FY2024 figure was $1.7 million, 17.44% down from the prior year.
  • Short term Debt for Q3 2025 was $4.5 million at Profound Medical, up from $1.7 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.5 million in Q3 2025 and troughed at $523000.0 in Q4 2022.
  • A 5-year average of $2.2 million and a median of $1.8 million in 2022 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: plummeted 62.96% in 2022 and later soared 302.29% in 2023.
  • Year by year, Short term Debt stood at $1.4 million in 2021, then plummeted by 62.96% to $523000.0 in 2022, then soared by 302.29% to $2.1 million in 2023, then dropped by 17.44% to $1.7 million in 2024, then surged by 157.92% to $4.5 million in 2025.
  • Business Quant data shows Short term Debt for PROF at $4.5 million in Q3 2025, $1.7 million in Q4 2024, and $2.1 million in Q4 2023.